Author

Sandra Abrevaya

February 9, 2024

A New Era of Care: What to Expect from Synapticure in 2025 and Beyond

Sandra Abrevaya, CEO and Co-founder of Synapticure, shares the company's plans for the future after announcing the successful completion of their $25M Series A funding.
February 9, 2024

Announcing a New Advisory Relationship with The Michael J. Fox Foundation

Synapticure announces The Michael J. Fox Foundation as its newest advisor to help improve access to specialty care and to accelerate Parkinson’s research
February 9, 2024

Synapticure Launches an IRB-Approved Study for Presymptomatic Carriers of Pathogenic, ALS-Associated Gene Variants

February 9, 2024

Synapticure Patient Panel - 01/12/23

February 9, 2024

Improving outcomes and accelerating treatments through data-driven, remote, proactive care

February 9, 2024

What does it cost to see a Synapticure MD in-network?

The financial and time stress of ALS is real. We aim to reduce both so you can focus on living

It is time to leave behind the era of

“I’m sorry but we can’t help you.”

Book your visit
Patients & Families
How It WorksFrequently Asked Questions
For Partners
ProvidersPayersGUIDEResearch
Our Services
Alzheimer's DiseaseFrontotemporal DementiaALS & PLSParkinson's DiseaseHuntington's DiseaseMental Health Care
About us
Leadership TeamOur CliniciansCareersCollaborators & SupportersContact
Resources
Our BlogPress Releases
Legal
Privacy PolicyTerms of ServiceNotice of Privacy PracticesConsumer Health Data Privacy PolicyTelehealth Informed ConsentFCOINondiscrimination Notice

This office appreciates the diversity of human beings and does not discriminate based on race, age, religion, ability,  marital status, sexual orientation, sex or gender identity.

Synapticure logo whitePh: +1 708-630-1534
Fax: +1 888-517-8619

2045 W Grand Ave Ste B Chicago, IL 60612

AICPA SOC 2 logo
© Copyright Synapticure. All rights reserved.